Rapid recovery from T lymphopenia by CD28 superagonist therapy.

Slow recovery of T-cell numbers and function contributes to the high incidence of life-threatening infections after cytotoxic cancer therapies. We have tested the therapeutic potential of a novel class of superagonistic CD28-specific antibodies that induce polyclonal T-cell proliferation without T-cell receptor engagement in an experimental rat model of T lymphopenia. We show that in lethally irradiated, bone marrow-reconstituted hosts, CD28 superagonist is able to dramatically accelerate repopulation by a small inoculum of mature, allotype-marked T cells. CD28-driven recovery of CD4 cells was superior to that of CD8 T cells. CD28 superagonist- expanded CD4 T cells had maintained repertoire diversity and were functional both in vitro and in vivo, suggesting that treatment with a human CD28-specific superagonist will protect T-lymphopenic patients from opportunistic infections.

[1]  T. Hanke,et al.  Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists , 2003, The Journal of experimental medicine.

[2]  D. Margulies.  CD28, Costimulator or Agonist Receptor? , 2003, The Journal of experimental medicine.

[3]  T. Hünig,et al.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist , 2003, European journal of immunology.

[4]  Stephen C. Jameson,et al.  Maintaining the norm: T-cell homeostasis , 2002, Nature Reviews Immunology.

[5]  C. Benoist,et al.  Cytokine Requirements for Acute and Basal Homeostatic Proliferation of Naive and Memory CD8+ T Cells , 2002, The Journal of experimental medicine.

[6]  J. Sprent,et al.  Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells , 2002, The Journal of experimental medicine.

[7]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[8]  D. Klatzmann,et al.  Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. , 2001, Blood.

[9]  S. Fulda,et al.  Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. , 2001, Blood.

[10]  A. Khoruts,et al.  Homeostatic Expansion Occurs Independently of Costimulatory Signals1 , 2001, The Journal of Immunology.

[11]  C. June,et al.  The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. , 2001, Cancer journal.

[12]  D. Kemeny,et al.  Activation‐induced cell death of human T‐cell subsets is mediated by Fas and granzyme B but is independent of TNF‐α , 2001, Journal of leukocyte biology.

[13]  T. Fry,et al.  Interleukin-7: master regulator of peripheral T-cell homeostasis? , 2001, Trends in immunology.

[14]  L. Lum,et al.  Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28–Costimulated T Cells—Phase I Clinical Trial , 2001, Journal of immunotherapy.

[15]  T. Fry,et al.  IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. , 2001, Blood.

[16]  N. Gruta,et al.  Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire , 2000, European journal of immunology.

[17]  S. Jameson,et al.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo , 2000, Nature Immunology.

[18]  E. Rubenstein.  Colony stimulating factors in patients with fever and neutropenia. , 2000, International journal of antimicrobial agents.

[19]  C. Mackall.  T‐Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review , 2000, The oncologist.

[20]  B. Levine,et al.  T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. , 1999, Journal of immunotherapy.

[21]  C. Mackall,et al.  Thymic aging and T‐cell regeneration , 1997, Immunological reviews.

[22]  S. Chanock,et al.  Therapy‐Induced Alterations in Host Defense in Children Receiving Therapy for Cancer , 1997, Journal of pediatric hematology/oncology.

[23]  T. Hanke,et al.  CD28‐mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28 , 1997, European journal of immunology.

[24]  R. Vabulas,et al.  Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation‐associated apoptosis , 1996, European journal of immunology.

[25]  C. Mackall,et al.  Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. , 1996, Journal of immunology.

[26]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[27]  A. Cosimi,et al.  Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. , 1996, Transplantation.

[28]  C. Thompson,et al.  CD28 and apoptosis. , 1995, Current opinion in immunology.

[29]  M. Dallman,et al.  Cellular distribution and costimulatory function of rat CD28. Regulated expression during thymocyte maturation and induction of cyclosporin A sensitivity of costimulated T cell responses by phorbol ester. , 1995, Journal of immunology.

[30]  K. Heeg,et al.  Superantigen mediated shock: a cytokine release syndrome. , 1993, Immunobiology.

[31]  J. Allison,et al.  Identification and distribution of the costimulatory receptor CD28 in the mouse. , 1992, Journal of immunology.

[32]  P. Vereerstraeten,et al.  RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.

[33]  J. Hansen,et al.  Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen) , 1985, The Journal of experimental medicine.

[34]  Jeffrey A. Bluestone,et al.  CD28 Function: A Balance of Costimulatory and Regulatory Signals , 2004, Journal of Clinical Immunology.

[35]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[36]  L. Lum,et al.  Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial. , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[37]  T. Hünig,et al.  Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. , 1999, European journal of immunology.

[38]  D. Liebowitz,et al.  Adoptive T-cell therapy. , 1999, Seminars in hematology.

[39]  R. Golub,et al.  Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? , 1999, Seminars in hematology.

[40]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.